HeberNasvac, a Therapeutic Vaccine for Chronic Hepatitis B, Stimulates Local and Systemic Markers of Innate Immunity: Potential Use in SARS-CoV-2 Postexposure Prophylaxis

INTRODUCTION: More than 180 million people have been infected by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and more than 4 million coronavirus disease-2019 (COVID-19) patients have died in 1.5 years of the pandemic. A novel therapeutic vaccine (NASVAC) has shown to be safe and to...

Descripción completa

Detalles Bibliográficos
Autores principales: Fleites, Yoel A, Aguiar, Jorge, Cinza, Zurina, Bequet, Monica, Marrero, Elieser, Vizcaíno, Maritania, Esquivel, Idelsis, Diaz, Marisol, Sin-Mayor, Adriana, Garcia, Maura, Martinez, Sara M, Beato, Abrahan, Galarraga, Ana G, Mendoza-Mari, Yssel, Valdés, Iris, García, Gerardo, Lemos, Gilda, González, Isabel, Canaán-Haden, Camila, Figueroa, Nelvis, Oquendo, Rachel, Akbar, Sheikh MF, Mahtab, Mamun A, Uddin, Mohammad H, Guillén, Gerardo E, Muzio, Verena L, Pentón, Eduardo, Aguilar, Julio C
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Jaypee Brothers Medical Publishers 2021
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8566153/
https://www.ncbi.nlm.nih.gov/pubmed/34786358
http://dx.doi.org/10.5005/jp-journals-10018-1344

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8566153/
https://www.ncbi.nlm.nih.gov/pubmed/34786358
http://dx.doi.org/10.5005/jp-journals-10018-1344

Ejemplares similares